Recording of a SPECIAL PANEL SESSION at the
Foundation of the American Society of Neuroradiology Annual Meeting on May 21, 2016 in Washington, DC

5300-301A Gadolinium Deposition & the
Safety of MRI Contrast Agents

What do we know?
What don’t we know?
What do we need to know?

A certified 45-minute discussion for MRI radiologists

Hot off the Press!

• ACR–ASNR POSITION STATEMENT ON THE USE OF GADOLINIUM CONTRAST AGENTS Issued May 2016
• ACR Manual on Contrast Media Version 10.2, 2016

Course Overview
The use of gadolinium-based contrast agents in MR imaging has been well-established and remains an extremely valuable tool for diagnosis and treatment management. Recent data regarding gadolinium deposition in patients who have undergone contrast-enhanced MRI is rapidly evolving. Further research is needed to evaluate the clinical significance, if any, of these findings. In the meantime, radiologists and referring physicians must ensure informed decision-making about the benefits and potential risks to patients undergoing a contrast-enhanced MRI examination.

Educational Objectives
After completing this activity, participants should be better able to:

• Describe how the physiochemical properties and classification of GBCAs may affect patient safety
• Discuss recent studies reporting the discovery of gadolinium deposits in patients who have undergone contrast-enhanced MRI exams
• Summarize what is known and not known at this time regarding the clinical significance of gadolinium deposition in patients
•  Implement current FDA, ACR, and ASNR guidelines for GBCA usage

ACCME Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and International Center for Postgraduate Medical Education. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Physicians
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

SA-CME: This activity meets the criteria for self-assessment toward the purpose of fulfilling requirements in the American Board of Radiology (ABR) Maintenance of Certification Program.

The European Accreditation Council for CME (EACCME®)
The UEMS-EACCME® has mutual recognition agreements with the American Medical Association (AMA) for live events and e-learning materials. For more information go to http://www.uems.eu/uems-activities/accreditation/eaccme.

How to Participate
There are no fees or prerequisites for this program.

• Click ENROLL NOW, then CONTINUE, CONFIRM ORDER, and ACCESS COURSE NOW
• Click on the blue link to view the course.
• Click on PLAYBACK.

How to Receive Credit

• Log-in to your account at www.icpme.us
• View the entire session. You will be redirected to the ICPME website.
• From the COURSE HOME page, click the button for POSTTEST and for EVALUATION.
• A passing grade of at least 75% is required to receive credit. You may take the test up to three times.
• Upon receipt of a passing grade, you will be able to print a certificate of credit from your account at www.icpme.us

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

The faculty has reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Max Wintermark, MD has received fees for non-CME/CE services from the GE NFL Advisory Board.
David M. Mirsky, MD has no disclosures to report.
Kirk M. Welker, MD, has no disclosures to report.

The following planners and managers have reported NO financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Trace Hutchison, PharmD                                  Victoria Phoenix, BS
Linda McLean, MS                                              Jan Schultz, RN, MSN, CCMEP
Samantha Mattiucci, PharmD, CCMEP           Judi Smelker-Mitchek, RN, BSN

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Questions?
For questions regarding this program, please contact ICPME:
Email: information@icpmed.com
Phone: 607-257-5860 x10

Jointly Provided by

This activity is supported by an independent educational grant from Bayer Healthcare Pharmaceuticals.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.